FDA Determines Regulatory Review Period for VERLUMA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of human biological product VERLUMA, as required by law, following a submission to the US Department of Commerce.